ZVA Stock Chart & Stats
€2.51
€0.01(0.40%)
At close: 4:00 PM EDT
€2.51
€0.01(0.40%)
Day’s Range― - ―
52-Week Range€2.18 - €4.65
Previous CloseN/A
Volume0.00
Average Volume (3M)364.00
Market Cap
€178.50M
Enterprise Value€218.11
Total Cash (Recent Filing)€185.47M
Total Debt (Recent Filing)€82.33M
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Aug 06, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding72,325,455
10 Day Avg. Volume0
30 Day Avg. Volume364
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)6.52
Price to Sales (P/S)6.52
P/FCF Ratio-11.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.77
Revenue Forecast (FY)€50.46M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~79% gross margins indicate the company's platform and manufacturing can capture high per-unit value, providing structural operating leverage as revenues scale. High gross margins improve the path to eventual profitability if R&D and SG&A growth are controlled over coming quarters.
Proprietary Allogeneic PlatformOwning a gene‑editing/allogeneic cell therapy platform is a durable competitive asset: it addresses a broader patient pool than autologous approaches, supports differentiation, and underpins long-term partnerships, licensing, and scale advantages in manufacturing and IP monetization.
Partnership-driven Revenue ModelA business model anchored in collaborations, licensing, and milestone payments provides recurring non‑commercial revenue streams that can fund R&D and manufacturing investments without immediate product sales. This structure reduces reliance on single product launches and supports longer investment horizons.
Bears Say
Large Cash BurnPersistent negative operating and free cash flow at scale signals ongoing funding requirements. Over 2–6 months this reduces flexibility, increases dependence on external financing or partner payments, and heightens dilution or liquidity risk if cash burn isn't curtailed or offset by new collaborations.
Rising Leverage And Shrinking EquityElevating debt-to-equity and a declining equity base materially weaken balance-sheet flexibility. Higher leverage increases fixed obligations and restrains the company's ability to secure non-dilutive financing or absorb trial setbacks, creating a structural funding vulnerability in the medium term.
Deep Negative ProfitabilityExtremely negative margins and recurring operating losses show the cost base far outpaces current revenue. Without sustained revenue growth or meaningful cost reductions, operating leverage remains negative, prolonging dependence on external capital and delaying any durable path to profitability.
Cellectis SA News
ZVA FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was €2.18 and its highest was €4.65 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is €178.50M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Aug 06, 2026 which is in 2 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on May 11, 2026. The company reported -€0.153 earnings per share for the quarter, beating the consensus estimate of -€0.221 by €0.068.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Overvalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.23.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,325,455 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -€0.153 in its last earnings report, beating expectations of -€0.221. Following the earnings report the stock price went down -0.826%.
Which hedge fund is a major shareholder of Cellectis SA?
Currently, no hedge funds are holding shares in DE:ZVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectis SA
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute myeloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.
ZVA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in advancing pivotal clinical trials and maintaining a strong financial position, with ongoing collaborations and upcoming strategic events. However, ongoing arbitration and a decrease in cash reserves posed challenges.View all DE:ZVA earnings summaries